Association between immunophenotypic markers and cytogenetic aberrations in Egyptian patients with plasma cell myeloma

Boshnak, Noha H; Hashem, Azza E

doi:10.4103/1110-1067.206433

Cited by 5 publications

(7 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike the results of our study, Boshnak and Hashem found that CD56 positivity was associated with advanced stage 14 . However, the results of Ceran et al 17 agree with our results, as CD56 expression was found to have no effect on clinical behavior.…”

Section: Discussioncontrasting

confidence: 99%

“…CD56 is a homophilic binding glycoprotein implicated in cell-cell adhesion that is involved in attaching plasma cells to the stromal structure of the bone marrow 1 . The prevalence of CD56 positivity in MM varied among studies 11,[14][15][16] . In the current study, 84% of patients were CD56 positive, which is much higher than the 42% prevalence found by Boshnak and Hashem 14 .…”

Section: Discussionmentioning

confidence: 99%

“…The prevalence of CD56 positivity in MM varied among studies 11,[14][15][16] . In the current study, 84% of patients were CD56 positive, which is much higher than the 42% prevalence found by Boshnak and Hashem 14 . Other studies done by Pan et al 11 , Qiu et al 15 and Shim et al 16 reported a prevalence of 71%, 61% and 66%; which is not much lower than that in our study.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Value of CD56 Expression in Multiple Myeloma

Khallaf

Yousof

Ahmed

et al. 2020

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Background: Understanding the prognostic markers of multiple myeloma (MM) helps in optimizing therapeutic approaches. CD56 is frequently expressed by malignant plasma cells and its use as a prognostic marker in MM is promising. Aim: To evaluate prognostic value of CD56 expression in patients with MM. Methods: This study included 50 newly diagnosed patients with MM. Bone marrow samples were analyzed for CD56 expression by flow cytometry. All patients received bortezomib-based therapy for at least 3-4 months. Results: The median age of patients was 52 years (range 32-75) and 54% of them were males. The stage according to the International Staging System was I in 15 (30%) patients, II in 18 (36%) and III in 17 (34%). CD56 positivity was detected in 84% of enrolled patients. Multivariate analysis revealed that the lack of CD56 expression was an independent predictor of worse overall survival (HR = 4.31 [95% Confidence Interval: 1.23 -15.13], p = 0.002). Conclusion:The present study suggests that CD56 negativity is associated with poor prognosis in patients with MM and that its incorporation in the risk panel of MM may be considered. Further studies with larger sample size to validate its prognostic value are needed.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of CD56 Expression in Multiple Myeloma

Khallaf

Yousof

Ahmed

et al. 2020

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

show abstract

“…Hence, CD45 positivity in PCM cells could indicate negative prognostic implications 50 . Our study found a CD45-negative rate of 76.9%, which is higher than the rates reported in equivalent studies: 50% 45 , 30% 44 , and 22.6% 46 . This suggests that our PCM cases potentially have more positive prognostic implications.…”

Section: Discussioncontrasting

confidence: 82%

“…In PCM cells, fewer than 5% express CD19 44 . We found that 28.2% of cases were CD19-positive, which is significantly higher than the 8.8% observed among Koreans 45 but lower than the 38.7% among Egyptians 46 . This indicates that such variations may reflect population genetic heterogeneity.…”

Section: Discussioncontrasting

confidence: 68%

Immunophenotypic Expression and its Association with Prognostic Factors, Clinical Stages, and Clinical Profiles in Newly Diagnosed Patients with Plasma Cell Myeloma: Insights from Two Tertiary Care Centers

Ismail,

Chi,

Yusoff

et al. 2024

Biomed. Res. Ther.

View full text Add to dashboard Cite

Objective: Plasma cell myeloma (PCM) is an incurable clonal neoplasm of plasma cells, which typically presents a poor prognosis. This study aimed to determine the clinical profile of newly diagnosed plasma cell myeloma cases in two tertiary care centers in Malaysia and evaluate the association of aberrant immunophenotypic expression with prognostic factors and clinical stages. Methods: A four-year retrospective study of 78 newly diagnosed PCM cases was conducted at Hospital Kuala Lumpur (HKL) and Hospital Universiti Sains Malaysia (HUSM). The study retrieved data from medical records, including socio-demographic characteristics, hematological and biochemical parameters, cytogenetic and molecular abnormalities, immunophenotypic expression profile, and clinical stages of PCM cases. All data were statistically analyzed using SPSS 26.0. Results: The mean age of PCM patients was 60 years, with 73.1% of cases showing a normal white blood cell (WBC) count. A total of 65.4% and 24.4% of cases had anemia and mild to severe anemia, respectively. Cases were associated with thrombocytopenia (24.4%), normal platelet counts (75.6%), a bone marrow plasma cell percentage >10% (93.6%), and elevated erythrocyte sedimentation rate (ESR) (63.3%). Additionally, 66.7% of cases demonstrated hypoalbuminemia and elevated lactate dehydrogenase (LDH), calcium, and creatinine levels. All cases indicated hyperproteinemia (56.4%), hypoproteinemia (6.4%), normal serum total protein (37.2%), elevated serum paraprotein (69.2%), and blood beta-2 microglobulin (B2M) (62.5%) levels, as well as aberrant cytogenetic abnormalities (16.7%). The cases were grouped into Stage III (39.7%), Stage II (24.4%), and Stage I (5.1%). CD38 and CD138 demonstrated 100% expression, with every case exhibiting expression of more than one aberrant antigen, including CD19 (28.2%), CD45 (23.1%), CD56 (83.3%), CD117 (25.6%), kappa (60.3%), and lambda light chain (38.5%). However, only CD19 markers and serum creatinine levels exhibited a statistically significant association (p = 0.036). Conclusion: Immunophenotyping by multiparametric flow cytometry is powerful in distinguishing PCM from normal cells. The aberrant antigens expressed in this study displayed a heterogeneous immunophenotypic profile unique to our population. However, to enhance outcome and robustness of this study, it is recommended to engage additional centers purposefully to increase the sample size.

show abstract